Integration of Trastuzumab, with or without Pertuzumab, into Perioperative Chemotherapy of HER2- Positive Stomach Cancer: The INNOVATION Trial (EORTC-1203-GITCG).
ثبت نشده
چکیده
This international, randomized phase II trial is a collaboration between EORTC (leading group), the Korean Cancer Study Group, who committed to recruit 50% of the patients, and the Dutch Upper GI Cancer Group. It has been designed to assess the impact of integrating trastuzumab alone and the combination of trastuzumab and pertuzumab in the perioperative treatment of resectable, HER-2 positive adenocarcinoma of the stomach, on the major
منابع مشابه
Escalating and de-escalating treatment in HER2-positive early breast cancer.
The current standard adjuvant systemic treatment of early HER2-positive breast cancer consists of chemotherapy plus 12months of trastuzumab, with or without endocrine therapy. Several trials have investigated modifications of the standard treatment that are shorter and less resource-demanding (de-escalation) or regimens that aim at dual HER2 inhibition or include longer than 12months of HER2-ta...
متن کاملThe expanding role of pertuzumab in the treatment of HER2-positive breast cancer
Pertuzumab, a humanized monoclonal antibody to the HER2 receptor, represents a promising new anti-HER2 agent with a novel mechanism of action targeting the inhibition of HER2 dimerization. Nonclinical and clinical data to date indicate that pertuzumab provides a broader HER2 blockade through the inhibition of HER2 heterodimerization. In preclinical experiments, pertuzumab has demonstrated super...
متن کاملPertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Overexpression of HER2 - found in approximately 15-20% of all breast cancers - is a negative prognostic factor. Although trastuzumab significantly improves the prognosis of HER2-positive breast cancer, half of the patients with metastatic breast cancer experience disease progression within 1 year. Pertuzumab is a novel HER2-targeted humanized monoclonal antibody that binds to the dimerization d...
متن کاملOverview of the CLEOPATRA Trial: Implications for Advanced Practitioners
G enomic biomarkers have long been known as predictors of pharmacokinetic differences among individuals that lead to differences in plasma drug exposure. Overexpression of the human epithelial growth factor receptor (HER2) proto-oncogene is seen in about 25% of human breast cancer and leads to a more aggressive tumor phenotype with a poor prognosis (Rexer & Arteaga, 2012). In recent years, this...
متن کاملPertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models.
PURPOSE We investigated the antitumor activity of the combination of two different humanized monoclonal human epidermal growth factor receptor (HER) 2 antibodies, pertuzumab and trastuzumab, for gastric cancer. EXPERIMENTAL DESIGN Tumor mouse xenograft models were used to examine antitumor activity. Cell proliferation was examined using crystal violet staining. HER family proteins' expression...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Oncology research and treatment
دوره 39 3 شماره
صفحات -
تاریخ انتشار 2016